| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2014-08-29 | Orexo (Sweden) | SEK 346.5 million (€37.7 million) | private placement | Swedish and international external institutional and strategic investors | CNS diseases | Private placement |
| 2014-08-29 | Blueprint Genetics (Finland) | $3.9 Million (€ 2.97 million) | fundraising | Inventure (Finland) Avohoidon Tutkimussäätiö (Finland) | Technology - Services | Fundraising |
| 2014-08-20 | SimPrints (UK) | £ 0.5 million (€0.62 million) | grant | Bill and Melinda Gates Foundation (USA) ARM Ltd (UK) | Technology - Services | Grant |
| 2014-08-19 | Auris Medical (Switzerland) | $60.7 million | IPO | Otorhinolaryngology | IPO | |
| 2014-08-13 | Novosanis (Belgium) | € 0.25 million | grant | Flemish Agency for Innovation by Science and Technology (IWT) (Belgium) | Grant | |
| 2014-08-13 | Ablynx (Belgium) | €2.1 million | grant | Flemish Agency for Innovation by Science and Technology (IWT) (Belgium) | Ophtalmological diseases | Grant |
| 2014-08-08 | Jazz Pharmaceuticals (Ireland) | private placement | Cancer - Oncology - CNS diseases | Private placement | ||
| 2014-08-05 | Phosphagenics (Australia) | A$19.3 million (€13.3 million) | private placement | institutional and sophisticated investors in Europe, USA, Asia and Australia | Technology - Services - CNS diseases | Private placement |
| 2014-08-05 | Diurnal (UK) | up to £6 million (€ 7.54 million) | fundraising | IP Group (UK) | Hormonal diseases - Endocrine diseases | Fundraising |
| 2014-07-31 | Macrocure (Israel) | $ 54 million (€ 40.3 million) | IPO | Regenerative medicine | IPO | |
| 2014-07-31 | Fate Therapeutics (USA - CA) | up to $20 million | long-term debt financing | Silicon Valley Bank (USA - CA) | Rare diseases | Loan |
| 2014-07-30 | VBL Therapeutics (Israel) | IPO | Cancer - Oncology - Immunological diseases - Inflammatory diseases | IPO | ||
| 2014-07-30 | Bio Blast Pharma (Israel) | $ 35.2 million (€ 26.1 million) | IPO | Rare diseases - Genetic diseases | IPO | |
| 2014-07-30 | Innocoll (Ireland) | $ 51.5 million (€ 38.4 million) | IPO | Sofinnova Partners (France) | Medical devices | IPO |
| 2014-07-28 | Ceva Santé Animale (France) | undisclosed | LMBO | Mérieux Développement (France) Temasek (Singapore) CDH Investments (China) Euromezzanine (France) Sagard (France) | Veterinary medicine | Fundraising |
| 2014-07-24 | Atox Bio (Israel) | $23 Million | Series E financing round | SR One (UK) Lundbeckfond Ventures (Denamrk) OrbiMed Israel (Israel) | Infectious diseases | Financing round |
| 2014-07-24 | Xention (UK) | £1.4 million (€1.77 million) | grant | Technology Strategy Board (UK) | Cardiovascular diseases | Grant |
| 2014-07-24 | University of Birmingham (UK) Biotie Therapies (Finland) | € 1 million | grant | National Institute for Health Research (NIHR) (UK) | Inflammatory diseases | Grant |
| 2014-07-24 | 4SC (Germany) Crelux (Germany) | undisclosed | grant | m4 - Personalised Medicine and Targeted Therapies\' programme of the German Federal Ministry of Research and Education (BMBF) (Germany) | Cancer - Oncology | Grant |
| 2014-07-22 | 3P Biopharmaceuticals (Spain) | € 6 million | capital increase | Infarco (Spain) | Technology - Services | Capital increase |
